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1Antiplatelet drugs are a cornerstone of preventive therapy for patients at risk of atherothrombotic events. Typically, 
these patients take low-dose aspirin (≈75–100 mg) once a day. 
Patients requiring further protection, such as following acute 
coronary syndrome, particularly with ST-segment–elevation, 
or percutaneous coronary intervention, take a P2Y12 receptor 
blocker, most commonly clopidogrel, in addition to aspirin.1–4 
This dosing regimen is commonly known as dual antiplatelet 
therapy (DAPT). Despite these therapeutic approaches, subse-
quent thrombotic events still occur and research has focused 
on ways to quantify individual patient risk. As a result, the 
concepts of antiplatelet drug resistance and high on-treatment 
platelet reactivity have developed.5–11 Through this research, it 
has become apparent that patients who have conditions asso-
ciated with increased platelet turnover also have particularly 
elevated risks.4,12–15 Collectively, these observations lead to the 
idea that increased risk while on antiplatelet therapy may be 
explained by the relationship between the pharmacokinetic 
and pharmacodynamic properties of aspirin and P2Y12 inhibi-
tors, and the dynamic changes associated with turnover of the 
platelet population.
Aspirin is rapidly absorbed from the stomach and small 
intestine reaching a plasma peak around 1 hour later.16 It is 
then rapidly metabolized by esterases in the gut, liver, and cir-
culation and has a circulating half-life of 13 to 19 minutes. 
Overall, this means that little active aspirin remains in the 
body 2 to 3 hours after consumption. However, as aspirin irre-
versibly acetylates and blocks the cyclooxygenase (COX)-1 
enzyme in platelets, and as anucleated platelets are limited in 
their ability to generate new COX-1, the inhibitory effect of 
aspirin on platelets persists for their entire life span of 7 to 
12 days.4,17 The thienopyridine P2Y12 blockers, clopidogrel 
© 2015 The Authors. Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters 
Kluwer. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in 
any medium, provided that the original work is properly cited.
Arterioscler Thromb Vasc Biol is available at http://atvb.ahajournals.org DOI: 10.1161/ATVBAHA.115.306219
Objective—Reduced antiplatelet drug efficacy occurs in conditions of increased platelet turnover, associated with increased 
proportions of drug-free, that is, uninhibited, platelets. Here, we detail mechanisms by which drug-free platelets promote 
platelet aggregation in the face of standard antiplatelet therapy.
Approach and Results—To model standard antiplatelet therapy, platelets were treated in vitro with aspirin, the P2Y12 receptor 
blocker prasugrel active metabolite, and aspirin plus prasugrel active metabolite. Different proportions of uninhibited 
platelets were then introduced. Light transmission aggregometry analysis demonstrated clear positive associations 
between proportions of drug-free platelets and percentage platelet aggregation in response to a range of platelet agonists. 
Using differential platelet labeling coupled with advanced flow cytometry and confocal imaging, we found aggregates 
formed in mixtures of aspirin-inhibited platelets and drug-free platelets were characterized by intermingled platelet 
populations. This distribution is in accordance with the ability of drug-free platelets to generate thromboxane A2 and so 
drive secondary platelet activation. Conversely, aggregates formed in mixtures of prasugrel active metabolite–inhibited 
or aspirin plus prasugrel active metabolite–inhibited platelets together with drug-free platelets were characterized by 
distinct cores of drug-free platelets. This distribution is consistent with the ability of drug-free platelets to respond to the 
secondary activator ADP.
Conclusions—These experiments are the first to image the interactions of inhibited and uninhibited platelets in the 
formation of platelet aggregates. They demonstrate that a general population of platelets can contain subpopulations 
that respond strikingly differently to overall stimulation of the population and so act as the seed for platelet 
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and prasugrel, are prodrugs with complex pharmacokinetics 
requiring metabolism to thiolactone active metabolites that 
are irreversible receptor antagonists of platelet P2Y12 recep-
tors.18–20 Like aspirin, these active metabolites are short lived 
in the circulation but produce long-lasting effects because of 
irreversible inhibition of their target. Given these pharmaco-
kinetic and pharmacodynamic profiles of aspirin and clopi-
dogrel/prasugrel, we can reason that platelets that enter the 
circulation after the drugs have been cleared will not be inhib-
ited and that the proportion of circulating drug-free platelets 
will increase in proportion to the rate of platelet turnover. 
Elevated rates of platelet production are associated with many 
conditions/procedures which feature increased thrombotic 
risk including patients undergoing coronary artery bypass 
surgery21 or those with diabetes mellitus,22–27 chronic kidney 
disease,28,29 metabolic syndrome,30 and essential thrombo-
cythemia.31,32 In these patient groups, increased circulating 
subpopulations of uninhibited platelets may be of crucial 
importance in providing the seed for the formation of occlu-
sive platelet thrombi. Drug-free platelets could also drive the 
changes noted in ex vivo tests of platelet reactivity.
In the in vitro study reported here, we have assessed the 
impact of drug-free platelet subpopulations on overall plate-
let responses to antiplatelet therapy by modeling the entry 
of drug-free platelets into the circulation and used confocal 
microscopy and flow cytometric imaging to provide unique 
images of the interactions of inhibited and drug-free platelet 
subpopulations in the formation of platelet aggregates. These 
studies provide insight into potential mechanisms underly-
ing the disease-associated incidence of thrombotic events and 
illustrate important concepts relevant to ideas of antiplatelet 
drug resistance.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Influence of Drug-Free Platelets on Light 
Transmission Aggregometry Responses
First, we modeled the effects of drug-free platelets on 
responses recorded by light transmission aggregometry (LTA) 
having previously established the effectiveness of antiplatelet 
drugs (Table I in the online-only Data Supplement). Increasing 
proportions of drug-free platelets were added to inhib-
ited platelet populations, and the net aggregatory responses 
were recorded (Figure 1; Figure II in the online-only Data 
Supplement). Aggregation to the COX-1 substrate arachidonic 
acid (AA; 1 mmol/L) in an aspirin-inhibited platelet popula-
tion was returned to a full response by the inclusion of 30% 
drug-free platelets (Figure 1Ai). In general terms, increasing 
aggregation was seen with increasing platelet number in the 
absence of drug, that is, shifting from platelet-poor plasma 
to platelet-rich plasma (Figure III in the online-only Data 
Supplement). Measurement of thromboxane B2 (TXB2) as a 
measure of the formation of the COX product TxA2 demon-
strated a linear increase of TXB2 with increasing proportions 
of drug-free platelets (R2=0.8867), ranging from 1.6±0.4 ng/
mL TXB2 when 0% platelets were aspirin-free to 1220±126 
ng/mL when 100% platelets were aspirin-free (Figure 1C). 
Similarly, aggregation to AA (1 mmol/L) in a prasugrel active 
metabolite (PAM)–inhibited platelet population was returned 
to a full response by the inclusion of 60% drug-free platelets 
(Figure 1Aii), and 80% drug-free platelets in the presence of 
an aspirin+PAM-inhibited platelet population (Figure 1Aiii). 
In each case, this relationship was nonlinear.
In contrast, for the P2Y12 receptor ligand ADP, there was 
a linear increase in aggregation that followed the addition 
of drug-free platelets to platelets inhibited with either PAM 
or aspirin+PAM (Figure 1B and 1C). For instance, in PAM-
inhibited platelets, addition of 20%, 40%, and 80% drug-free 
platelets increased aggregation from the control level of 4±3% 
to 13±5%, 29±8%, and 53±5%, respectively. Conversely, the 
addition of drug-free platelets to PAM-treated platelets led to 
an inverse relationship with phosphorylation of vasodilator-
stimulated phosphoprotein, a downstream measure of P2Y12 
inhibition, in the total platelet population (Figure IV in the 
online-only Data Supplement). Aspirin alone had little effect 
on aggregation induced by ADP and so responses of aspirin-
inhibited platelets were minimally affected by the addition 
of drug-free platelets (Figure 1Ai). Similarly, aggregation in 
response to U46619 was linearly related to rising proportions 
of drug-free platelets mixed with PAM- or aspirin+PAM-
inhibited platelets, but insensitive to aspirin-treatment (Figure 
II in the online-only Data Supplement).
Aspirin or PAM alone partially inhibited aggregations 
induced by the primary stimulus collagen or the glycoprotein 
(GP) VI agonist collagen-related peptide, which were returned 
to full responses by the addition of 40% or 60% to 80% drug-
free platelets, respectively. The combination of aspirin+PAM 
required 80% drug-free platelets for the aggregation to col-
lagen to return to a full response and 60% for collagen-related 
peptide (Figure II in the online-only Data Supplement).
Similar to the first series of experiments (Table I in the 
online-only Data Supplement), responses to ristocetin were 
unaffected by aspirin (Figure 1Ai), PAM (Figure 1Aii), or 
aspirin+PAM (Figure 1Aiii), consistent with the mechanism 
of action of ristocetin being platelet agglutination rather than 
platelet activation, and so independent of the generation of 
secondary mediators of aggregation.
In inhibited platelet populations, lumiaggregometry con-
firmed that the increases in platelet aggregations in response 
to AA or ADP following addition of increasing proportions of 
drug-free platelets correlated with matched increases in plate-
let release of ATP (Figure 1B). For example, aggregations 
Nonstandard Abbreviations and Acronyms
AA arachidonic acid
COX cyclooxygenase
DAPT dual antiplatelet therapy
GP glycoprotein
LTA light transmission aggregometry
PAM prasugrel active metabolite
TX thromboxane
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induced by AA in the presence of 10%, 40%, and 80% aspi-
rin-free platelets were 1±1%, 60±6%, and 74±3%, whereas 
the accompanying releases of ATP were 0, 3±0.1, and 4±1 
nmol/108 platelets.
In order to mimic physiologically more relevant condi-
tions, aggregation was also stimulated by the combination 
of subthreshold concentrations of the platelet agonists ADP, 
collagen, thrombin receptor activator peptide-6, and U46619. 
Aggregation in an inhibited platelet population was returned 
to a full response by the inclusion of 40% drug-free platelets 
in the presence of aspirin, 60% drug-free platelets in the pres-
ence of PAM, and 80% drug-free platelets in the presence of 
aspirin+PAM (Figure IID in the online-only Data Supplement).
Aspirin-Free Platelets Intermingle With 
Aspirin-Inhibited Platelets, Whereas Pam-
Free Platelets Form Clusters in the Center of 
Aggregates Covered in PAM-Inhibited Platelets
To elucidate the contribution of drug-free platelets to platelet 
aggregation, the morphologies of aggregates containing mixed 
platelet subpopulations were characterized by confocal imag-
ing. Platelet aggregates comprising aspirin-inhibited platelets 
with a 20% subpopulation of drug-free platelets were charac-
terized by intermingling of platelet populations (Figure 2A). 
Conversely, aggregates formed from combinations of 80% 
PAM-inhibited platelets and 20% drug-free platelets demon-
strated clear clustering of drug-free platelets to the cores of 
Figure 1. Light transmission aggregation, thromboxane A2 (TXA2) formation, and ATP-release in inhibited platelet-rich plasma (PRP) 
containing rising proportions of drug-free platelets. A, Effects of adding drug-free PRP to PRP inhibited with aspirin (30 µmol/L; Ai), 
prasugrel active metabolite (PAM, 3 µmol/L; Aii), and aspirin+PAM (Aiii) on aggregatory responses to arachidonic acid (AA; 1 mmol/L), 
ADP (20 µmol/L), or ristocetin (2 mg/mL). Curves were constructed from multiple aggregatory responses using final aggregation values 
obtained by traditional light transmission aggregometry (LTA) after 5-minute aggregation. Percentage aggregation values are presented 
as mean±SEM of experiments using platelets prepared from 6 to 8 individuals. ***P<0.001, **P<0.01, and *P<0.05 difference by paired 
ANOVA in aggregation from 0% drug-free platelets. B, Percentage aggregation and release of ATP, a measure of granule release, stimu-
lated by AA or ADP in PRP pretreated with aspirin (30 µmol/L; Bi) or PAM (3 µmol/L), respectively, (Bii) mixed with increasing proportions 
of drug-free PRP. Curves were constructed from multiple aggregatory responses using aggregation values obtained by traditional LTA 
after 5 minutes and maximum ATP released measured by CHRONOLUME assay. Percentage aggregation values and ATP-release values 
are presented as mean±SEM of experiments using platelets prepared from 4 individuals for each comparative point. C, Concentrations 
of TXB2, a measure of TXA2, in unstimulated PRP or rising proportions of drug-free PRP mixed with aspirin-treated PRP on stimulation by 
AA (1 mmol/L). Values are presented as mean±SEM of experiments using platelets prepared from 4 individuals. ***P<0.001, **P<0.01, and 
*P<0.05 difference by paired ANOVA in aggregation from 0% aspirin-free platelets.
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platelet aggregates on stimulation by ADP or AA. Aggregates 
formed by stimulation of the mixed platelet populations with 
ristocetin were always characterized by intermingled platelet 
populations (Figure 2B). Analysis of confocal images revealed 
5× greater clustering of drug-free platelets in the presence of 
PAM after ADP stimulation than the clustering after stimula-
tion by ristocetin.
In further studies, a full range of combinations of PAM-
treated platelets or the clinically relevant combination of 
aspirin+PAM-treated platelets with drug-free platelets were 
examined. In these experiments, the central clustering of 
drug-free platelets in aggregates increased in proportion to the 
fraction of drug-free platelets (Figure 3).
GP IIb/IIIa Mediates Recruitment of 
PAM-Inhibited Platelets to the Aggregate 
Core Independently of TXA2
To assess the contribution of TXA2 potentially formed by 
the drug-free core to the association of inhibited plate-
lets to the platelet aggregates, mixed subpopulations con-
taining drug-free and PAM-treated platelets were treated 
with aspirin (thereby inhibiting TXA2 formation) or 
Figure 2. Interaction between aspirin- or prasugrel active metabolite (PAM)–inhibited platelets and a drug-free subpopulation of platelets. 
Confocal images of platelet aggregates formed from combined platelet populations containing 80% aspirin-inhibited (red, A) or PAM-
inhibited (red, B) platelets and 20% drug-free (green) platelets. Washed platelet aggregates were obtained at the end of 5-minute light 
transmission aggregometry (LTA) responses stimulated by arachidonic acid (AA; 250 µmol/L), ADP (20 µmol/L), or ristocetin (2 mg/mL). 
For experiments, platelet suspensions were pretreated with aspirin (30 µmol/L), PAM (3 µmol/L), or corresponding vehicle for 20 minutes, 
washed and labeled with either PKH67 (green) or PKH26 (red) before mixing and stimulation. Images were processed with Imaris software 
to show images of inhibited (red) and drug-free (green) platelets. Bottom row of both panel sets show 5-µm median focal sections. Scale 
bars indicate 20 µm. Each image is representative of images from platelets prepared from at least 4 different individuals.
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corresponding vehicle before aggregation to ADP. Analysis 
of confocal images indicated no difference in the ratio of 
PAM-inhibited to drug-free platelet volume in formed 
aggregates in the absence (1.15±0.35) or presence of aspirin 
(1.02±0.15; Figure 4A). This was further supported by flow 
cytometry–based imaging analysis demonstrating no differ-
ence in measured area of PAM-inhibited platelets between 
different treatments over a wide range of platelet proportions 
(Figure 4B).
Addition of the GP IIb/IIIa-inhibitor abciximab to PAM-
inhibited platelets reduced their binding to the drug-free plate-
let aggregate core (0.48±0.11 versus 1.71±0.19, P<0.05, n=4), 
indicating the association of PAM-inhibited platelets to the 
core was not an artifact of the imaging procedure (Figure 5A).
Figure 3. Interaction between prasugrel active metabolite (PAM) or aspirin+PAM-inhibited platelets and a drug-free subpopulation of plate-
lets. Three-dimensional (3D) reconstruction and median sections of confocal images of platelet aggregates formed from combined platelet 
populations containing 90% to 20% PAM-inhibited platelets (red, left panels) or aspirin+PAM-inhibited platelets (red, right panels) and 10% 
to 80% drug-free platelets (green). Washed platelet aggregates were obtained at the end of 5-minute light transmission aggregometry (LTA) 
responses stimulated by ADP (20 µmol/L). For experiments, platelet suspensions were pretreated with aspirin (30 µmol/L) plus PAM (3 µmol/L) 
or corresponding vehicle for 20 minutes, washed and labeled with either PKH67 (green) or PKH26 (red) before mixing and stimulation. Images 
were processed with Imaris software to show combined images of inhibited (red) and drug-free (green) platelets. Scale bars indicate 10 µm.
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The involvement of GP IIb/IIIa in the recruitment of PAM-
inhibited platelets was confirmed by traditional flow cytometry 
and flow cytometric imaging analyses. Addition of abciximab 
to the inhibited platelet population reduced the measured 
platelet area of PAM-inhibited platelets associated with drug-
free platelets (Figure 5B) and further caused a strong reduc-
tion in the incorporation of inhibited platelets into platelet 
aggregates as measured by a reduced number of aggregates 
containing both platelet subpopulations(Figure 5C).
To further elucidate the underlying mechanism causing 
the recruitment of PAM-treated platelets into the drug-free 
platelet core, fibrinogen-binding studies were performed. 
The drug-free core was associated with the highest pro-
portion of fibrinogen per volume of drug-free platelets 
(0.52±0.10) followed by the PAM-treated shell (0.17±0.03) 
and the control platelet sample (0.01±0.01; Figure 6A). 
A similar pattern was found in the 60% drug-free propor-
tion mixed with 40% PAM-treated platelets (fibrinogen/
drug-free core, 0.45±0.3; fibrinogen/PAM-treated shell, 
0.1±0.06; control, 0.01±0.01; data not shown). Flow 
cytometry analysis of fibrinogen binding to platelet sub-
populations (Figure 6B) confirmed these findings (eg, 80% 
Figure 4. Aspirin has no effect on the association of inhibited platelets to prasugrel active metabolite (PAM)–free platelet aggregates. Ai, 
Confocal images of platelet aggregates formed from combined platelet populations containing 80% PAM-inhibited or 80% aspirin+PAM-
inhibited platelets (red) and 20% drug-free or aspirin-inhibited (green) platelets. Washed platelet aggregates were obtained at the end of 
5-minute light transmission aggregometry (LTA) responses stimulated by ADP (20 µmol/L). For experiments, platelet suspensions were 
pretreated with PAM (3 µmol/L), PAM (3 µmol/L) plus aspirin (30 µmol/L), aspirin (30 µmol/L), or corresponding vehicle for 20 minutes, 
washed and labeled with either PKH67 (green) or PKH26 (red) before mixing and stimulation. Images were processed with Imaris software 
to show combined images of PAM-inhibited (red) and drug-free/aspirin-treated platelets (green). Scale bars indicate 10 µm. Each image is 
representative of images from platelets prepared from at least 4 different individuals. Aii, Six confocal images per condition were analyzed 
for ratios between red and green platelet volume. Volumes of platelet subpopulations were calculated by Imaris software, and different 
treatments were compared by t test and found not to be significantly different. Scatter plots of combined platelet subpopulations consist-
ing of 20% drug-free and 80% PAM-inhibited platelets in the absence (Bi) or presence of aspirin (Bii) post stimulation by ADP (20 µmol/L). 
Biii, Aggregates containing drug-free platelets were gated in region PAM-free positive and then analyzed by ImageStream. Ch1 shows 
the bright field image, Ch2 and Ch3 show the channel for PAM-free and PAM-inhibited platelets, respectively (scale bars indicate 14 
µm). Washed platelet aggregates were obtained at the end of 5 minutes LTA responses stimulated by ADP (20 µmol/L). For experiments, 
platelet suspensions were pretreated with PAM (3 µmol/L), aspirin (30 µmol/L) plus PAM (3 µmol/L), aspirin (30 µmol/L), or corresponding 
vehicle for 20 minutes, washed and labeled with either PKH67 (green) or PKH26 (red) before mixing and stimulation. Biv, ImageStream 
data from 4 experiments were analyzed for the area of inhibited platelets associated with drug-free platelets over a range of platelet sub-
population proportions in the absence or presence of aspirin. Different treatments were compared by 2-way ANOVA and found not to be 
significantly different for all tested proportions.
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Figure 5. Effect of abciximab pretreatment on the interaction of drug-free and P2Y12-inhibited platelet subpopulations. Ai, Confo-
cal images of platelet aggregates formed from combined platelet populations containing 80% prasugrel active metabolite (PAM)- or 
PAM+abciximab-inhibited platelets (red) and 20% drug-free platelets (green). Washed platelet aggregates were obtained at the end of 
5-minute light transmission aggregometry (LTA) responses stimulated by ADP (20 µmol/L). Images were processed with Imaris software. 
Scale bars indicate 10 µm. Each image is representative of images from platelets prepared from at least 4 different individuals. Aii, Six 
confocal images per experiment were analyzed for the ratios of red and green platelet volume. Volumes of platelet subpopulations were 
calculated by Imaris software and different treatments were compared by t test and determined as P=0.0013 between aggregates con-
taining PAM-inhibited platelets mixed with drug-free platelets and aggregates containing PAM+abciximab-inhibited platelets and drug-free 
platelets. Data represent mean±SEM of 4 experiments. Scatter plots of combined platelet subpopulations consisting of 20% drug-free 
and 80% PAM-inhibited platelets (Bi) or 20% drug-free and 80% PAM+abciximab-inhibited platelets (Bii) post stimulation by ADP (20 
µmol/L) obtained by ImageStream flow cytometry. For experiments, platelet suspensions were pretreated with PAM (3 µmol/L), PAM (3 
µmol/L) plus abciximab (10 µmol/L), or corresponding vehicle for 20 minutes, washed and labeled with either PKH67 (green) or PKH26 
(red) before mixing and stimulation. Biii, Flow cytometry–derived images of platelet aggregates formed from combined platelet populations 
containing 80% PAM-inhibited or PAM+abciximab-inhibited platelets (red) and 20% drug-free platelets (green; gated PAM-free positive 
in Bi or Bii). Ch1 shows the bright field images, Ch2 and Ch3 show the channels for drug-free and PAM- or PAM+abciximab-inhibited 
platelets, respectively (scale bars indicate 14 µm). For analyses, washed platelet aggregates were obtained at the end of 5-minute LTA 
responses stimulated by ADP (20 µmol/L). Biv, Images obtained during flow cytometry of 4 experiments were analyzed for inhibited plate-
lets associated with drug-free platelets over a range of platelet combinations and treatments and compared by 2-way ANOVA. ***P<0.001 
and *P<0.05, n=4. C, Flow cytometry analysis was performed after 5-minute aggregation stimulated by ADP (20 µmol/L) in PAM- or 
PAM+abciximab-inhibited platelets in the presence of rising proportions of drug-free platelets. Events positive for PKH26 (inhibited plate-
lets) and PKH67 (drug-free platelets) were identified as microaggregates. Data points represent mean±SEM of samples prepared from 5 
individuals. ***P<0.001 and *P<0.05 differences of microaggregates containing drug-free and PAM-treated platelets compared with micro-
aggregates containing drug-free and PAM+abciximab-treated platelets compared with control responses by paired ANOVA; n=6, for each.
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PAM-treated platelets: vehicle stimulated, 2.4±0.4%; ADP-
stimulated, 6.2±0.6%; P<0.01), indicating that GP IIb/
IIIa, but not TXA2, is involved in the recruitment of PAM-
inhibited platelets to the drug-free platelet core.
Discussion
The confocal analyses we present here, together with quantita-
tive data from LTA, indicate that overall aggregation responses 
in mixed populations of inhibited and drug-free platelets are 
underpinned by distinct patterns of interaction that differ 
between inhibition of platelet COX by aspirin and blockade 
of platelet P2Y12 receptors by thienopyridines. These find-
ings define processes underlying in vitro platelet tests used to 
assess P2Y12 receptor blocker and aspirin effectiveness5–11 and 
provide insight to the potential interactions of platelet popula-
tions in vivo.
Others have previously reported that in tests of platelet 
reactivity conducted in vitro a relatively small population of 
Figure 6. Fibrinogen is associated with both, the drug-free core and the P2Y12-inhibited shell. Ai, Confocal images of platelet aggregates 
formed from combined platelet populations containing 80% prasugrel active metabolite (PAM)–inhibited platelets (red) and 20% drug-
free platelets (green) in the presence of AlexaFluor647-conjugated fibrinogen. Washed platelet aggregates were obtained at the end of 
5-minute light transmission aggregometry (LTA) responses stimulated by ADP (20 µmol/L). Images were processed with Imaris software. 
Scale bars indicate 10 µm. Each image is representative of images from platelets prepared from at least 4 different individuals. Aii, Four 
confocal images per experiment were analyzed for the concentration of labeled fibrinogen associated with either red or green platelet 
volume. Volumes of platelet subpopulations were calculated with Imaris software, and fibrinogen concentrations per platelet volume were 
compared by t test and determined as P=0.0012 or P=0.002 between fibrinogen associated with unstimulated and ADP-stimulated PAM-
treated platelets or drug-free platelets, respectively. Bi, Representative flow cytometric scatter plots of drug-free or PAM-treated platelet 
subpopulations against AlexaFluor647-conjugated fibrinogen fluorescence (x axis) following stimulation with saline or ADP (20 µmol/L). 
Gated events were considered positive for fibrinogen binding and occurrence (%) calculated. Bii, Fibrinogen bound platelets (%) of drug-
free or PAM-treated platelet populations across all tested proportions. Comparison by 1-way ANOVA found significantly higher fibrinogen 
binding in PAM-treated proportions compared with vehicle (saline) stimulated control. ***P<0.001, **P<0.01, and *P<0.05. Data represent 
mean±SEM of 4 to 5 experiments for all.
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aspirin naïve platelets can support full platelet aggregation, 
subject to the stimulus being applied. For instance, di Minno et 
al15 demonstrated that in LTA with platelet-rich plasma ≈10% 
drug-free platelets could support a full aggregation response 
to collagen (1 μg/mL) plus AA (1 mmol/L). More recent stud-
ies have associated reduced effectiveness of aspirin in vivo 
to increased platelet turnover as defined by the proportion of 
reticulated platelets in the circulation.33 Similar analyses have 
indicated that increased proportions of reticulated platelets are 
associated with reduced effectiveness of clopidogrel in both 
rats34 and humans,35 in humans receiving DAPT of aspirin 
plus clopidogrel,36,37 and most recently in humans receiving 
DAPT of aspirin plus prasugrel.38 Studies of the duration of 
drug action after treatment withdrawal also indicate that the 
return of aggregatory responses is commensurate with the 
time for replenishment of circulating platelets.39 In the first 
part of our studies, we modeled these effects in LTA using a 
panel of platelet agonists40 and rising proportions of drug-free 
platelets against a background of standard antiplatelet ther-
apy, aspirin and aspirin plus prasugrel (by the use of PAM). 
We also studied PAM alone and provided aggregation curves 
from serially diluted platelet-rich plasma to assist in interpre-
tation of data. Considering first the agonists most sensitive 
for testing the effects of aspirin, that is, AA and PAM, that 
is, ADP, we noted that whereas addition of 30% of drug-free 
platelets could return full responses to AA in the presence of 
aspirin, 80% of drug-free platelets were required to return full 
responses to ADP in the presence of PAM or aspirin+PAM. 
Aspirin and P2Y12 receptor blockers have different targets on 
the platelet and inhibit with different functional modalities. 
Aspirin inhibits platelet COX-1, and so the ability of platelets 
to produce TXA2. This does not stop aspirin-inhibited platelets 
responding to TXA2 produced by aspirin-free platelets, and so 
the hypothesis has developed that a minority of aspirin-free 
platelets are capable of generating sufficient TXA2 to support 
a full aggregatory response.4,17,41 While the in vivo propor-
tion of aspirin uninhibited platelets required to provide a full 
response has been suggested to be as low as 5% or less,41 the 
response of a population of platelets to a particular concentra-
tion of TXA2 will depend on their existing state of activation 
Figure 7. Schematic diagram of the platelet activation mechanisms resulting from presence of drug-free platelets in populations of 
aspirin-inhibited and dual antiplatelet-inhibited platelets. In aspirin-inhibited platelet populations mixed with drug-free platelets (upper), 
activation of cyclooxygenase-1 in drug-free platelets leads to thromboxane A2 (TXA2) formation and release. Formed TXA2 acts equally 
on both aspirin-inhibited and drug-free platelets, leading to activation and aggregate formation characterized by random intermingling of 
platelet subpopulations. In aspirin+PAM-inhibited platelets (modeling DAPT with an irreversible P2Y12 receptor blocker) combined with 
drug-free platelets, exposure to ADP causes activation of the drug-free subpopulation and its clustering. This leads to formation of a dis-
tinct uninhibited core that promotes activation of the inhibited platelets. In this way, through different mechanisms, drug-free platelets act 
as the seed for platelet aggregate formation in the presence of both aspirin and DAPT. AA indicates arachidonic acid.
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so there is unlikely to be a particular proportion relevant in all 
conditions; although clearly even a small subset of platelets 
can produce enough TXA2 to aggregate a larger population.
PAM, by blocking P2Y12 receptors, inhibits the ability of 
a platelet to respond to ADP released by other activated plate-
lets. Unlike the effects of aspirin, the blockade of one plate-
let’s P2Y12 receptors cannot be compensated for by lack of 
blockade on another platelet; hence, we found a linear rela-
tionship between drug-free platelets and the response to ADP. 
For the other platelet agonists, we noted composite responses 
as expected from their relative dependencies on the TXA2 and 
P2Y12 receptor pathways. For example, collagen and collagen-
related peptide activate both pathways; U46619 is sensitive to 
blockade of P2Y12 receptors, because TXA2 receptor activation 
leads to ADP release, but not to the effects of aspirin. Consistent 
with this, AA stimulates the generation of TXA2 and so is sensi-
tive both to aspirin, by inhibition of COX, and to PAM, because 
of inhibition of TXA2 receptor amplification.42–44 Overall, in the 
presence of aspirin+PAM, which models the effects of DAPT 
using aspirin and a thienopyridine, all agonists demonstrated 
increasing responses with increasing proportions of drug-free 
platelets. The exception was ristocetin, which we included as a 
control agent, because it causes platelet agglutination that does 
not require active platelet involvement.45
Our confocal and flow cytometric imaging studies per-
mitted a unique and deeper exploration of the interactions 
between inhibited and drug-free platelet populations. Notably, 
drug-free platelets were distributed throughout aggregates of 
aspirin-inhibited platelets, whereas drug-free platelets formed 
clear cores within PAM- or aspirin+PAM-inhibited plate-
let aggregates. We conclude that the intermingled pattern of 
drug-free and aspirin-inhibited platelets is consistent with the 
drug-free subset driving the aggregatory response by produc-
ing TXA2 throughout the platelet mixture. In this study, we 
have not examined the roles of COX-1 and COX-2 isoforms 
because we have used mature platelet populations, but in vivo 
newly formed platelets may express COX-2, which could 
provide a further level of complexity in the responsiveness to 
aspirin as could non-COX effects of aspirin.9,31,46 Conversely, 
platelets with blocked P2Y12 receptors cannot equally respond 
to the effects of ADP, do not become activated by ADP 
released as part of platelet amplification pathways, so are not 
part of platelet aggregate cores. It is interesting to contemplate 
that platelets with their P2Y12 receptors blocked are entirely 
mixed with drug-free platelets in our system, yet after addition 
of a platelet activator the drug-free platelets bind to each other 
so assembling an activated core from the larger mixed platelet 
population.
Our imaging studies primarily concentrated on the effects 
of a population of 20% drug-free platelets. This ratio is what 
could be expected under a once-daily drug regimen in condi-
tions, such as diabetes mellitus, in which circulating platelet 
lifetimes are ≈5 days.13,23,26 For completeness, we also charac-
terized a range of combinations between 10% drug-free and 
80% drug-free platelets. These studies demonstrated in PAM-
inhibited or aspirin+PAM-inhibited platelets that the size of 
the drug-free platelet aggregate core grew with the propor-
tion of drug-free platelets, whereas inhibited platelets were 
only ever associated with the outer portion. Furthermore, we 
found that addition of aspirin did not reduce the association of 
inhibited platelets, indicating that this was not dependent on 
the formation of TXA2. However, the recruitment of P2Y12-
inhibited platelets to the forming aggregate was the result of 
active aggregation because these inhibited platelets bound 
fibrinogen more than unstimulated control platelets, and their 
association to the drug-free core was reduced by the GP IIb/
IIIa blocker abciximab.
In summary, our studies shed new light on the responses 
recorded in many studies of ex vivo platelet reactivity and 
their association to antiplatelet drug therapy. Although it 
has previously been hypothesized that subpopulations of 
aspirin-free platelets act as individual generators of TXA2, 
we demonstrate for the first time a mechanism by which this 
is achieved; aspirin-free platelets are distributed through-
out aspirin-inhibited platelet aggregates allowing generated 
TXA2 to activate a larger proportion of platelets (Figure 7). 
In contrast, platelets free of inhibition by irreversible P2Y12 
receptor blockers, such as clopidogrel and prasugrel, form 
the core of platelet aggregates and act as the nexus for the 
formation of larger aggregates because P2Y12 receptor inhib-
ited platelets are drawn in via other activation pathways. For 
DAPT, this leads to a complicated interaction between the 
ability of a minority of aspirin uninhibited platelets to drive 
a full TXA2-dependent response and a linear relationship 
between P2Y12 receptor blockade and platelet aggregation. 
Aggregatory responses, measured by LTA, have been asso-
ciated with thrombotic risk and these have been linked to 
particular patient groups in which increased platelet turnover 
occurs.4,12–15 Our in vitro studies clearly indicate that such 
an increased ratio of drug-free platelets may be potentially 
critical to modulating thrombotic risk in conditions that are 
associated with increased platelet turnover, such as diabetes 
mellitus, chronic kidney disease, metabolic syndrome, and 
essential thrombocythemia. This is consistent with twice a 
day administration of aspirin providing an improved anti-
platelet effect compared with standard once a day therapy in 
such patient groups.13,26,27,32,47 In essence, our studies indicate 
that in a patient receiving antiplatelet therapy in the form of 
either aspirin or DAPT consisting of aspirin plus a thienopyr-
idine, a drug-free subpopulation can exist that will respond 
differently to platelet activators. This differential interaction 
and its potential to drive thrombosis are important both to 
consideration of individualized therapies and to the develop-
ment of antiplatelet strategies.
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Many individuals at risk of heart attacks and strokes receive prophylactic antiplatelet therapy, aspirin often with the addition of a thieno-
pyridine P2Y12 receptor blocker. Because of the short half lives of these drugs within the body and the continual release into the circulation 
of newly formed platelets, it has been hypothesized that significant populations of uninhibited platelets can emerge during standard once a 
day dosing. Here by modeling these events in vitro and imaging the interactions of different platelet populations, we have for the first time 
provided analysis of the potential underlying mechanisms and demonstrated that differently inhibited platelet subpopulations respond very 
differently to platelet activators. Understanding these mechanisms is central to modulating thrombotic risk in conditions that are associated 
with increased platelet turnover, such as diabetes mellitus, chronic kidney disease, metabolic syndrome, and essential thrombocythemia.
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SUPPLEMENTAL MATERIAL 
 
 
TABLES 
 
aggregatory 
stimulus 
% of control aggregation (vehicle-treated) 
aspirin  PAM  aspirin + PAM  
AA  2±2* 27±12* 4±2* 
ADP  76±6 7±4* 5±2* 
collagen  22±5* 56±15* 9±2* 
CRP-XL  53±10* 47±10* 37±10* 
ristocetin  85±8 95±7 115±9 
U46619  113±5 25±11* 24±7* 
  
Table SI.  In vitro effects of aspirin, PAM and aspirin+PAM on aggregatory responses 
of platelets. Percentage values of control vs aspirin (30 µmol/L), PAM (3 µmol/L) and 
aspirin+PAM aggregation in response to stimulation by AA (1 mmol/L), ADP (20 µmol/L), 
collagen (1 µg/ml), CRP-XL (0.1 µg/ml), ristocetin (2 mg/ml) and U46619 (1 µmol/L).   are 
presented as mean±SEM of experiments using platelets prepared from 6 individuals; * 
p<0.05 compared to control responses.      
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Figure SI: Schematic diagram summarising the experimental setup used for imaging 
platelet aggregates. 1 - platelet suspensions obtained from PRP; 2 – platelets labelled and 
treated with anti-platelet drugs; 3 – differently treated and labelled platelets combined in 
rising proportions; 4 – aggregation stimulated by a range of agonists; 5 – formed aggregates 
transferred to a microscope slide; 6 – aggregates imaged by confocal microscopy; 7 – 
images processed and analysed by Imaris software.  
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Figure SII: Light transmission aggregation in inhibited PRP containing rising 
proportions of drug-free platelets. Aggregatory responses to collagen (1 µg/ml), CRP-XL 
(0.1 µg/ml), U46619 (1 µmol/L) or ADP (5 µmol/L) after adding drug-free PRP to PRP 
inhibited with (A) aspirin (30 µmol/L), (B) PAM (3 µmol/L) and (C) aspirin+PAM. (D)  The 
aggregatory responses to the combination of ADP (0.1 µmol/L), collagen (0.1 µg/ml), TRAP-
6 (0.1 µmol/L) and U46619 (0.1 µmol/L) in drug-free PRP with (Di) aspirin, (Dii) PAM or (Diii) 
aspirin+PAM-inhibited PRP. Curves were constructed from multiple aggregatory responses 
using final aggregation values obtained by traditional LTA after five minutes aggregation. 
Percentage aggregation values are presented as mean±SEM of experiments using platelets 
prepared from 5-8 individuals. *** p<0.001, ** p<0.01 and * p<0.05 difference by paired 
ANOVA in aggregation from 100% drug-free platelets. 
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Figure SIII: Light transmission aggregation in PRP containing variable platelet 
concentrations.  Effects of variable platelet concentrations, obtained by centrifuging whole 
blood at different speeds, on aggregatory responses to A) AA (1 mmol/L), or B) ADP (20 
µmol/L). Data is presented as percentage of platelets obtained after centrifugation at 175 x g. 
Curves were constructed from multiple aggregatory responses using final aggregation values 
obtained by traditional LTA after five minutes aggregation. Percentage aggregation values 
and % platelets are presented as mean±SEM of experiments using platelets prepared from 3 
individuals.  
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Figure SIV: Phosphorylation of vasodilator stimulated phosphoprotein (VASP) in PRP 
containing rising proportions of drug-free platelets.  (A) Geometric mean fluorescence 
intensity of phospho(Ser239)-VASP, measured by flow cytometry after adding drug-free PRP 
to PRP inhibited with (PAM (3 µmol/L) and stimulated with ADP (20 µmol/L). B) 
Representative phospho(Ser239)-VASP fluorescence histograms of each PRP-proportion 
stimulated with ADP (20 µmol/L). Data are presented as mean±SEM of experiments using 
platelets prepared from 4 individuals. 
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